Exenterative pelvic surgery--eleven year experience of the Swansea Pelvic Oncology Group

Eur J Surg Oncol. 2005 Dec;31(10):1180-4. doi: 10.1016/j.ejso.2005.07.007. Epub 2005 Aug 26.

Abstract

Aims: To review indications for surgery and outcomes of patients with complex locally advanced pelvic malignancies treated by a multidisciplinary Pelvic Oncology Group.

Patients and methods: Between March 1992 and March 2003, 130 patients were jointly assessed in a monthly clinic involving urological, gynaecological, colorectal and plastic surgeons, an oncologist and nurse specialists. Seventy-six patients proceeded to exenterative surgery.

Results: Rectal carcinoma and gynaecological cancers were the two most common indications for surgery. Median follow-up was 14 months (range 1-120 months). There were no deaths within 30 days of surgery. The morbidity rate was 28%. Predicted 5 years survival was 53% in cases with clear histological margins and no lymph node metastasis.

Conclusion: With careful patient selection and multi specialty care pelvic exenteration is a safe and effective option in the treatment of complex locally advanced pelvic malignancy.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Care Team
  • Patient Selection
  • Pelvic Exenteration / mortality*
  • Pelvic Neoplasms / mortality
  • Pelvic Neoplasms / surgery*
  • Survival Analysis
  • Treatment Outcome